293 related articles for article (PubMed ID: 22152855)
1. Correlation between the number of segmental chromosome aberrations and the age at diagnosis of diploid neuroblastomas without MYCN amplification.
Souzaki R; Tajiri T; Teshiba R; Kinoshita Y; Yosue R; Kohashi K; Oda Y; Taguchi T
J Pediatr Surg; 2011 Dec; 46(12):2228-32. PubMed ID: 22152855
[TBL] [Abstract][Full Text] [Related]
2. Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Clin Cancer Res; 2003 Oct; 9(13):4835-40. PubMed ID: 14581355
[TBL] [Abstract][Full Text] [Related]
3. Evolution of unbalanced gain of distal chromosome 2p in neuroblastoma.
Stallings RL; Carty P; McArdle L; Mullarkey M; McDermott M; O'Meara A; Ryan E; Catchpoole D; Breatnach F
Cytogenet Genome Res; 2004; 106(1):49-54. PubMed ID: 15218241
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of DNA di-tetraploidy in neuroblastoma.
Ladenstein R; Ambros IM; Pötschger U; Amann G; Urban C; Fink FM; Schmitt K; Jones R; Slociak M; Schilling F; Ritter J; Berthold F; Gadner H; Ambros PF
Med Pediatr Oncol; 2001 Jan; 36(1):83-92. PubMed ID: 11464912
[TBL] [Abstract][Full Text] [Related]
5. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Clin Cancer Res; 2003 Jan; 9(1):52-8. PubMed ID: 12538451
[TBL] [Abstract][Full Text] [Related]
6. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome.
Brinkschmidt C; Christiansen H; Terpe HJ; Simon R; Lampert F; Boecker W; Dockhorn-Dworniczak B
Med Pediatr Oncol; 2001 Jan; 36(1):11-3. PubMed ID: 11464859
[TBL] [Abstract][Full Text] [Related]
7. Comparing histopathological classification with MYCN, 1p36 and 17q status detected by fluorescence in situ hybridisation from 14 untreated primary neuroblastomas in Singapore.
Yong MH; Hwang WS; Knight LA; Fung W; Chan MY; Seow WT; Chui CH
Singapore Med J; 2009 Nov; 50(11):1090-4. PubMed ID: 19960166
[TBL] [Abstract][Full Text] [Related]
8. MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.
Spitz R; Hero B; Skowron M; Ernestus K; Berthold F
Eur J Cancer; 2004 Dec; 40(18):2753-9. PubMed ID: 15571958
[TBL] [Abstract][Full Text] [Related]
9. Clinical Significance of Segmental Chromosomal Aberrations in Patients with Neuroblastoma: First Report in Korean Population.
Lim H; Son MH; Hyun JK; Cho HW; Ju HY; Lee JW; Yoo KH; Sung KW; Koo HH
J Korean Med Sci; 2020 Apr; 35(14):e82. PubMed ID: 32281311
[TBL] [Abstract][Full Text] [Related]
10. MYCN amplification and 17q in neuroblastoma: evidence for structural association.
O'Neill S; Ekstrom L; Lastowska M; Roberts P; Brodeur GM; Kees UR; Schwab M; Bown N
Genes Chromosomes Cancer; 2001 Jan; 30(1):87-90. PubMed ID: 11107180
[TBL] [Abstract][Full Text] [Related]
11. Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study.
Cohn SL; Look AT; Joshi VV; Holbrook T; Salwen H; Chagnovich D; Chesler L; Rowe ST; Valentine MB; Komuro H
Cancer Res; 1995 Feb; 55(4):721-6. PubMed ID: 7850780
[TBL] [Abstract][Full Text] [Related]
12. The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.
Bogen D; Brunner C; Walder D; Ziegler A; Abbasi R; Ladenstein RL; Noguera R; Martinsson T; Amann G; Schilling FH; Ussowicz M; Benesch M; Ambros PF; Ambros IM
Int J Cancer; 2016 Jul; 139(1):153-63. PubMed ID: 26910568
[TBL] [Abstract][Full Text] [Related]
13. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable
Ambros IM; Tonini GP; Pötschger U; Gross N; Mosseri V; Beiske K; Berbegall AP; Bénard J; Bown N; Caron H; Combaret V; Couturier J; Defferrari R; Delattre O; Jeison M; Kogner P; Lunec J; Marques B; Martinsson T; Mazzocco K; Noguera R; Schleiermacher G; Valent A; Van Roy N; Villamon E; Janousek D; Pribill I; Glogova E; Attiyeh EF; Hogarty MD; Monclair TF; Holmes K; Valteau-Couanet D; Castel V; Tweddle DA; Park JR; Cohn S; Ladenstein R; Beck-Popovic M; De Bernardi B; Michon J; Pearson ADJ; Ambros PF
J Clin Oncol; 2020 Nov; 38(31):3685-3697. PubMed ID: 32903140
[TBL] [Abstract][Full Text] [Related]
14. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma.
Spitz R; Hero B; Simon T; Berthold F
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3368-73. PubMed ID: 16740759
[TBL] [Abstract][Full Text] [Related]
15. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
16. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
17. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.
Caron H; van Sluis P; de Kraker J; Bökkerink J; Egeler M; Laureys G; Slater R; Westerveld A; Voûte PA; Versteeg R
N Engl J Med; 1996 Jan; 334(4):225-30. PubMed ID: 8531999
[TBL] [Abstract][Full Text] [Related]
18. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
[TBL] [Abstract][Full Text] [Related]
19. MYCN gain and MYCN amplification in a stage 4S neuroblastoma.
Noguera R; Cañete A; Pellín A; Ruiz A; Tasso M; Navarro S; Castel V; Llombart-Bosch A
Cancer Genet Cytogenet; 2003 Jan; 140(2):157-61. PubMed ID: 12645655
[TBL] [Abstract][Full Text] [Related]
20. Rapid and accurate determination of MYCN copy number and 1p deletion in neuroblastoma by quantitative PCR.
Anderson J; Gibson S; Williamson D; Rampling D; Austin C; Shipley J; Sebire N; Brock P
Pediatr Blood Cancer; 2006 Jun; 46(7):820-4. PubMed ID: 16220551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]